Abstract
Anti-inflammatory agents are routinely used to treat inflammatory diseases affecting both anterior and/or posterior segments of the eye. Corticosteroids and NSAIDs can be administered either topically onto the ocular surface structures or injected into the eye. However, one of the most important handicaps of ocular treatments is the presence of several anatomical and physiological barriers in the eye that drastically reduce drug access to the target site. The hydrophobicity of anti-inflammatory agents, low drug bioavailability, and the invasiveness of intraocular drug delivery are main reasons to explore the potential application of drug delivery-related technologies to develop new antiinflammatory ocular therapies. This review summarizes conventional anti-inflammatory treatments for ocular diseases and the ongoing research efforts to develop improved drug delivery systems. Micro-size intraocular implants, microparticles, nanoparticles, and liposomes are the preferred delivery systems in study.
Keywords: Anti-inflammatory drugs, corticosteroids, drug delivery, eye disease, nanomedicine, nanoparticles, NSAIDs, ocular drug administration, Ophthalmology, OCULAR ANTI-INFLAMMATORY THERAPY
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Drug Delivery Systems for Ophthalmic Administration of Antiinflammatory Agents
Volume: 10 Issue: 3
Author(s): Yolanda Diebold, Laura Contreras-Ruiz, Isabel Arranz-Valsero and Laura Garcia-Posadas
Affiliation:
Keywords: Anti-inflammatory drugs, corticosteroids, drug delivery, eye disease, nanomedicine, nanoparticles, NSAIDs, ocular drug administration, Ophthalmology, OCULAR ANTI-INFLAMMATORY THERAPY
Abstract: Anti-inflammatory agents are routinely used to treat inflammatory diseases affecting both anterior and/or posterior segments of the eye. Corticosteroids and NSAIDs can be administered either topically onto the ocular surface structures or injected into the eye. However, one of the most important handicaps of ocular treatments is the presence of several anatomical and physiological barriers in the eye that drastically reduce drug access to the target site. The hydrophobicity of anti-inflammatory agents, low drug bioavailability, and the invasiveness of intraocular drug delivery are main reasons to explore the potential application of drug delivery-related technologies to develop new antiinflammatory ocular therapies. This review summarizes conventional anti-inflammatory treatments for ocular diseases and the ongoing research efforts to develop improved drug delivery systems. Micro-size intraocular implants, microparticles, nanoparticles, and liposomes are the preferred delivery systems in study.
Export Options
About this article
Cite this article as:
Diebold Yolanda, Contreras-Ruiz Laura, Arranz-Valsero Isabel and Garcia-Posadas Laura, Drug Delivery Systems for Ophthalmic Administration of Antiinflammatory Agents, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (3) . https://dx.doi.org/10.2174/1871523011109030203
DOI https://dx.doi.org/10.2174/1871523011109030203 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture
Current Diabetes Reviews Safety and Efficacy of Dexamethasone Intravitreal Implant (Ozurdex) for the Treatment of Persistent Macular Edema Secondary to Retinal Vein Occlusion in Eyes Previously Treated with Anti-Vascular Endothelial Growth Factors
Current Drug Safety Anti-VEGF Molecules for the Management of Diabetic Macular Edema
Current Pharmaceutical Design The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets Polyunsaturated Fatty Acids in Pathological Retinal Angiogenesis
Current Nutrition & Food Science Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery The Medical and Medico-legal Complications of Bulimia Nervosa : Treatments and Complications
Current Women`s Health Reviews Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders
Current Molecular Medicine Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis
Recent Patents on Biomedical Engineering (Discontinued) Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design Intravitreal Dexamethasone Implant <i>versus</i> Intravitreal Ranibizumab Injection for Treatment of Non-Proliferative Diabetic Macular Edema: A Prospective, Randomized and Blinded Trial
Current Drug Delivery Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Cerebral Vascular Aging: Extending the Concept of Pulse Wave Encephalopathy Through Capillaries to the Cerebral Veins
Current Aging Science Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry “PARG Inhibitors’ Success: A Long Way to Go!”
Current Enzyme Inhibition Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology